A second KRAS blocker has won US approval, opening further a market in oncology based on a target that was once thought undruggable.
The US regulator has granted an Accelerated Approval to Mirati Therapeutics (Nasdaq: MRTX) for its Krazati (adagrasib), a targeted treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC).
To be eligible for treatment, patients must be assessed as having KRASG12C-mutated cancer, as determined by a biomarker test.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze